CTA Icon

In our new study learn about the latest NGS advances in myeloid fusion event detection

CytoCell Logo

Choose from over one hundred high-quality DNA FISH probes for the detection of genetic aberrations found in cancer and inherited genetic diseases.

Discover more
CytoSure Logo

Featuring the new constitutional NGS platform for cytogenetic research, alongside a broad range of arrays for rare disease and cancer research.

Discover more
SureSeq Logo

Choose from preloaded NGS panels for haematological and solid tumour cancer research or we can help you create your own.

Discover more

Try our handy FISH and NGS product tools

FISH chromosome search

View

Constitutional NGS chromosome search

View

Custom NGS cancer panel builder

View

Featured products

Simultaneously detect 30+ common fusions

SureSeq Myeloid Fusion NGS Panel

Developed in partnership with myeloid cancer experts to the latest WHO guidance, the panel can identify novel fusion partners — providing more comprehensive and informative analyses than possible using PCR-driven methods. The figure (right) shows the consistent and confident detection of MECOM overexpression in [A] serial dilutions of HNT-34 cell line as well as [B] research and commercial samples, including positive and negative controls.

Charts showing the SureSeq Myeloid Fusion NGS Panel

CytoCell FISH probes for AML and MDS analysis

New...Del(5q) Plus Tri-Colour Deletion & CBFB Breakapart Probes

The triple colour design of the Del(5q) Plus Tri-Colour Deletion Probe facilitates the detection of 5q interstitial proximal and distal deletions, in addition to monosomy 5 in AML and MDS analysis. The CytoCell CBFB Breakapart Probe, with its dual colour, dual fusion probe design, detects rearrangements in the 16q22 region and overcomes limitations associated with the proximity of signals on chromosome 16 during interphase FISH for AML detection.

Fluorescence in situ hybridisation (FISH) microscope images of Del(5q) Plus Tri-Colour Deletion and CBFC Breakapart probes.

The optimal solution for your FH research

CytoSure Comprehensive FH Panel

Familial Hypercholesterolaemia (FH) is a genetic condition which results in a high cholesterol level and subsequently leads to a higher risk of early heart disease. OGT is offering an optimised NGS panel which has selected the most relevant genes and SNPs implicated in FH, for your research needs. The figure (left) shows a double deletion on the LDLR gene, as visualised by Interpret software.

Next generation sequencing (NGS) software data showing a double deletion on the LDR gene.

Featured resources

View more resources and support

What binds us, makes us.

We believe that collaboration is key to improving patient lives. By sharing our knowledge and expertise, we ensure that we move forward with our customers, bound by a collective commitment to unlocking the future of genetic clinical care. See our story.

See our story of partnership (130 seconds) Image
Play the video.

See our story of partnership (130 seconds)

Latest OGT news

View all OGT News
OGT launches new SureSeq Myeloid Fusion Panel to help drive advances in myeloid cancer research   Image

OGT launches new SureSeq Myeloid Fusion Panel to help drive advances in myeloid cancer research

30 Apr 2024

Enables users to replace multiple techniques with a single streamlined NGS process for faster results.

Read
Group photo of OGT employees at the opening of the new office in Oxford

OGT expands NGS operations to state-of-the-art facility in Oxford Technology Park

07 Feb 2024

Investment in new premises to create increase in cutting-edge genomic solutions and collaborative partnerships.

Read
OGT to premiere SureSeq Myeloid MRD panel for AML disease monitoring at AMP Image

OGT to premiere SureSeq Myeloid MRD panel for AML disease monitoring at AMP

13 Nov 2023

New NGS assay delivers exceptional coverage, providing a rapid and highly sensitive means of investigating MRD in AML samples

Read
CTA Icon

Stay up-to-date with the latest news from OGT, including new products, support resources, and our DNA Dispatch newsletter